PT1551803E - Derivados azabiciclo como antagonistas do receptor muscarínico - Google Patents

Derivados azabiciclo como antagonistas do receptor muscarínico

Info

Publication number
PT1551803E
PT1551803E PT03762827T PT03762827T PT1551803E PT 1551803 E PT1551803 E PT 1551803E PT 03762827 T PT03762827 T PT 03762827T PT 03762827 T PT03762827 T PT 03762827T PT 1551803 E PT1551803 E PT 1551803E
Authority
PT
Portugal
Prior art keywords
receptor antagonists
muscarinic receptor
derivatives
azabicyclo
relates
Prior art date
Application number
PT03762827T
Other languages
English (en)
Inventor
Mohammad Salman
Anita Mehta
Pakala Kumara Savithru Sarma
Shankar Jayram Shetty
Sankaranarayanan Dharmarajan
Naresh Kumar
Arundutt Viswanatham Silamkoti
Anita Chugh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of PT1551803E publication Critical patent/PT1551803E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Plant Substances (AREA)
PT03762827T 2002-07-08 2003-04-11 Derivados azabiciclo como antagonistas do receptor muscarínico PT1551803E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/002663 WO2004004629A2 (en) 2002-07-08 2002-07-08 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
PT1551803E true PT1551803E (pt) 2007-01-31

Family

ID=30011691

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03762827T PT1551803E (pt) 2002-07-08 2003-04-11 Derivados azabiciclo como antagonistas do receptor muscarínico

Country Status (19)

Country Link
US (2) US7399779B2 (pt)
EP (2) EP1546099B1 (pt)
JP (2) JP2006502985A (pt)
CN (2) CN1668585A (pt)
AT (2) ATE419236T1 (pt)
AU (2) AU2002345266B2 (pt)
BR (2) BR0215801A (pt)
CA (2) CA2492121A1 (pt)
CY (1) CY1105879T1 (pt)
DE (2) DE60230683D1 (pt)
DK (1) DK1551803T3 (pt)
EA (3) EA200500173A1 (pt)
ES (1) ES2274275T3 (pt)
MX (2) MXPA05000434A (pt)
NZ (2) NZ537584A (pt)
PT (1) PT1551803E (pt)
SI (1) SI1551803T1 (pt)
WO (2) WO2004004629A2 (pt)
ZA (1) ZA200500951B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
AU2002353286A1 (en) 2002-12-10 2004-06-30 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1626957A1 (en) * 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
AP2006003592A0 (en) * 2003-10-14 2006-04-30 Pfizer Prod Inc Bicyclic [3.1.0] derivatives as glycine transporter inhibitors.
EP1746998A1 (en) * 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Combination therapy for lower urinary tract symptoms
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006003587A2 (en) * 2004-07-01 2006-01-12 Ranbaxy Laboratories Limited Solid oral dosage forms of azabicyclo derivatives
WO2006016245A1 (en) * 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1794161A2 (en) * 2004-09-24 2007-06-13 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20090176856A1 (en) * 2004-09-27 2009-07-09 Anita Mehta Muscarinic receptor antagonists
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
US20100035954A1 (en) * 2004-12-15 2010-02-11 Mohammad Salman Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
WO2007039884A1 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
EP1948164A1 (en) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of muscarinic receptor antagonists
KR20080089461A (ko) 2005-12-30 2008-10-06 랜박시 래보러터리스 리미티드 무스카린 수용체 길항제
EP1968980A1 (en) 2005-12-30 2008-09-17 Ranbaxy Laboratories, Ltd. Muscarinic receptor antagonists
US20100152269A1 (en) * 2006-12-21 2010-06-17 Ranbaxy Laboratories Limited Modified-release formulations of azabicyclo derivatives
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
CA3047002A1 (en) * 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
EP3823604A4 (en) 2018-07-17 2022-03-16 Board of Regents, The University of Texas System COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
CN111317754B (zh) * 2018-12-13 2022-02-18 泰州医药城国科化物生物医药科技有限公司 一种北豆根总碱的制备方法及应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490714A (en) 1947-05-13 1949-12-06 Du Pont Preparation of diazoacetic esters
NL267508A (pt) 1960-07-26
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5001160A (en) 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
IE66202B1 (en) 1989-08-16 1995-12-13 Pfizer Azabicyclo quinolone carboxylic acids
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5281601A (en) 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
FR2659323B1 (fr) * 1990-03-07 1992-06-12 Synthelabo Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
JPH0492921A (ja) 1990-08-03 1992-03-25 Fujitsu Ltd 指数関数演算器
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JPH0635958A (ja) 1992-07-14 1994-02-10 Hitachi Ltd 語句検索方法
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
ATE152302T1 (de) 1993-02-24 1997-05-15 Siemens Ag Sperrwandler-schaltnetzteil mit einem halbleiterschaltelement geringer spannungsfestigkeit
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
DE69632728T2 (de) 1995-04-28 2004-10-14 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituierte piperidinderivate
CA2179574A1 (en) 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
EP0863141B1 (en) 1995-10-13 2001-09-12 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
AU2793197A (en) 1996-05-31 1998-01-05 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
WO1998000109A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,r)-glycopyrrolate
WO1998000132A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,s)-glycopyrrolate
US6063808A (en) 1996-07-01 2000-05-16 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
US6319920B1 (en) 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP2003516390A (ja) 1999-12-07 2003-05-13 セラヴァンス インコーポレーテッド ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
ATE280162T1 (de) 2000-05-25 2004-11-15 Hoffmann La Roche Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
YU88902A (sh) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Supstituisani 1-aminoalkil laktami i njihova primena kao antagonista muskarinskih receptora
EP1294697A1 (en) 2000-06-14 2003-03-26 Muscagen Limited 1,2,3,5-tetrahydrobenzo[c]azepin-4-one derivatives having muscarinic antagonist activity
AU2001266100B9 (en) 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
EP1302458A4 (en) 2000-07-11 2005-10-19 Banyu Pharma Co Ltd ESTERDERIVATE
PL362989A1 (en) 2000-12-22 2004-11-15 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
EE05404B1 (et) 2000-12-28 2011-04-15 Almirall Prodesfarma Ag Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
WO2002083863A2 (en) * 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
WO2003033495A1 (en) 2001-10-17 2003-04-24 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
BR0214649A (pt) * 2001-12-03 2004-11-03 Hoffmann La Roche Derivados de aminotetralina como antagonistas do receptor muscarìnico
WO2003048124A1 (en) * 2001-12-03 2003-06-12 F. Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
US7265147B2 (en) 2002-07-31 2007-09-04 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
AU2002321711A1 (en) 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
CN1688544A (zh) 2002-08-23 2005-10-26 兰贝克赛实验室有限公司 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物
AU2002353286A1 (en) * 2002-12-10 2004-06-30 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
EP1590345A1 (en) 2002-12-23 2005-11-02 Ranbaxy Laboratories, Ltd. Xanthine derivatives as muscarinic receptor antagonists
WO2004056767A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7501443B2 (en) 2002-12-23 2009-03-10 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003205964A1 (en) * 2003-02-07 2004-08-30 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ATE362364T1 (de) 2003-04-10 2007-06-15 Ranbaxy Lab Ltd Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
US7560479B2 (en) * 2003-04-10 2009-07-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1626957A1 (en) 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
FR2855805B1 (fr) 2003-06-06 2005-08-05 Vallourec Vitry Element de structure pour vehicule, capable d'un meilleur comportement aux chocs
EP1746998A1 (en) 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Combination therapy for lower urinary tract symptoms
US20090176856A1 (en) 2004-09-27 2009-07-09 Anita Mehta Muscarinic receptor antagonists
US20100035954A1 (en) 2004-12-15 2010-02-11 Mohammad Salman Acid addition salts of muscarinic receptor antagonists

Also Published As

Publication number Publication date
ZA200500951B (en) 2006-07-26
EP1551803B1 (en) 2006-10-11
MXPA05000435A (es) 2005-04-19
CN1681784A (zh) 2005-10-12
NZ537585A (en) 2006-07-28
HK1079783A1 (en) 2006-04-13
ES2274275T3 (es) 2007-05-16
EP1546099B1 (en) 2008-12-31
US20060111425A1 (en) 2006-05-25
EA200500173A1 (ru) 2005-08-25
JP2006502985A (ja) 2006-01-26
JP2005535655A (ja) 2005-11-24
EA007932B1 (ru) 2007-02-27
AU2003226579A1 (en) 2004-01-23
NZ537584A (en) 2006-07-28
EA200501595A1 (ru) 2006-06-30
AU2002345266B2 (en) 2009-07-02
BR0215801A (pt) 2005-05-10
ATE419236T1 (de) 2009-01-15
CA2491998A1 (en) 2004-01-15
WO2004005252A1 (en) 2004-01-15
EP1546099A2 (en) 2005-06-29
CA2492121A1 (en) 2004-01-15
BR0312572A (pt) 2005-05-10
US7399779B2 (en) 2008-07-15
HK1082728A1 (en) 2006-06-16
EP1551803A1 (en) 2005-07-13
WO2004004629A3 (en) 2004-05-21
DK1551803T3 (da) 2007-02-19
DE60309057T2 (de) 2007-04-12
US20070004791A1 (en) 2007-01-04
US7544708B2 (en) 2009-06-09
SI1551803T1 (sl) 2007-02-28
WO2004004629A2 (en) 2004-01-15
EA009942B1 (ru) 2008-04-28
ATE342253T1 (de) 2006-11-15
EA200500172A1 (ru) 2005-08-25
DE60230683D1 (de) 2009-02-12
EP1551803B8 (en) 2006-12-13
EP1546099A4 (en) 2006-08-02
CN100519526C (zh) 2009-07-29
DE60309057D1 (de) 2006-11-23
CN1668585A (zh) 2005-09-14
AU2003226579B2 (en) 2009-01-22
AU2002345266A1 (en) 2004-01-23
CY1105879T1 (el) 2011-02-02
MXPA05000434A (es) 2005-04-19

Similar Documents

Publication Publication Date Title
ZA200500951B (en) Azabicyclo derivatives as muscarinic receptor antagonists
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
WO2004091514A3 (en) Cgrp receptor antagonists
WO2004092166A3 (en) Cgrp receptor antagonists
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
AU2002368152A1 (en) 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
AU2002353286A1 (en) 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2006041830A3 (en) Cgrp receptor antagonists
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) Flavaxate derivatives as muscarinic receptor antagonists
SI1673354T1 (sl) Arilindenopiridini in arilindenopirimidini in njihova uporaba kot antagonisti adenozinskih A2a-receptorjev
WO2006035282A3 (en) Muscarinic receptor antagonists
WO2006044449A3 (en) Cgrp receptor antagonists
HK1079708A1 (zh) 可用作毒蕈碱性受体拮抗剂的3，6-二取代氮杂二环[3．1．10]己烷衍生物
WO2006054162A8 (en) Azabicyclic muscarinic receptor antagonists
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
WO2006032994A3 (en) Muscarinic receptor antagonists
WO2007007281A3 (en) Muscarinic receptor antagonists
DE602004018844D1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate